Glucose-fructose oxidoreductase domain-containing protein 2 (GFOD2)

GFOD2 encodes a member of the Gfo/Idh/MocA family of oxidoreductases, enzymes characterized by their activity in electron transfer reactions involving NAD(P) and a diverse substrate range[4]. In human biology, GFOD2 is predicted and demonstrated to promote matrix assembly and is implicated in extracellular matrix organization, mainly within the extracellular region and matrix[2][1][9]. Its expression is cytoplasmic and found in diverse tissues, including the brain, endocrine glands, liver, and muscle[8][5]. Functional analyses indicate a role in processes that affect cell–cell communication and tissue remodeling, with limited evidence linking genetic variation to differential metabolic responses and malignant transformation[6][10]. Clinical relevance as a therapeutic target remains speculative, as no approved drugs are documented to modulate GFOD2 activity directly as of the current date.

Other names

GFOD2Gfo/Idh/MocA-like oxidoreductase domain containing 2Glucose-fructose oxidoreductase domain-containing protein 2UNQ9430/PRO34691FLJ23802MGC11335

Not established in reference to drug interaction, as no drugs are known to directly target GFOD2 at this time.